US4634665A
(en)
|
1980-02-25 |
1987-01-06 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5179017A
(en)
|
1980-02-25 |
1993-01-12 |
The Trustees Of Columbia University In The City Of New York |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
US5156840A
(en)
|
1982-03-09 |
1992-10-20 |
Cytogen Corporation |
Amine-containing porphyrin derivatives
|
US5057313A
(en)
|
1986-02-25 |
1991-10-15 |
The Center For Molecular Medicine And Immunology |
Diagnostic and therapeutic antibody conjugates
|
DE3883899T3
(de)
|
1987-03-18 |
1999-04-22 |
Sb2 Inc |
Geänderte antikörper.
|
IL162181A
(en)
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
DE3920358A1
(de)
|
1989-06-22 |
1991-01-17 |
Behringwerke Ag |
Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
|
JPH0395163A
(ja)
|
1989-09-08 |
1991-04-19 |
Daicel Chem Ind Ltd |
2.2.4.4.6―ペンタメチル―2.3.4.5―テトラヒドロピリミジンの製造法
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
JP4124480B2
(ja)
|
1991-06-14 |
2008-07-23 |
ジェネンテック・インコーポレーテッド |
免疫グロブリン変異体
|
EP0617706B1
(en)
|
1991-11-25 |
2001-10-17 |
Enzon, Inc. |
Multivalent antigen-binding proteins
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
US5731168A
(en)
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
ATE219517T1
(de)
|
1995-08-18 |
2002-07-15 |
Morphosys Ag |
Protein-/(poly)peptidbibliotheken
|
US20020077461A1
(en)
|
1996-04-24 |
2002-06-20 |
Soren Bjorn |
Pharmaceutical formulation
|
TR200201506T2
(tr)
|
1999-09-17 |
2002-10-21 |
Abbott Gmbh & Co. Kg |
Terapötik maddeler olarak kinaz inhibitörleri
|
CA2413330A1
(en)
|
2000-06-28 |
2002-01-03 |
Smithkline Beecham P.L.C. |
Wet milling process
|
JP2004525950A
(ja)
|
2001-04-06 |
2004-08-26 |
ワイス |
ラパマイシンとゲムシタビンまたはフルオロウラシルなどの、抗腫瘍剤の組み合わせ
|
GB0221697D0
(en)
|
2002-09-18 |
2002-10-30 |
Unilever Plc |
Novel compouds and their uses
|
AU2003272175A1
(en)
|
2002-10-21 |
2004-05-04 |
Aprea Ab |
Reactivation of wild type p53 in human tumour cells by a low molecular weight compound
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
AU2004205631A1
(en)
|
2003-01-16 |
2004-08-05 |
Genentech, Inc. |
Synthetic antibody phage libraries
|
US20050008625A1
(en)
|
2003-02-13 |
2005-01-13 |
Kalobios, Inc. |
Antibody affinity engineering by serial epitope-guided complementarity replacement
|
DE602004014747D1
(de)
|
2003-03-26 |
2008-08-14 |
Egalet As |
Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
|
JP4667383B2
(ja)
|
2003-06-13 |
2011-04-13 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
アグリコシル抗cd154(cd40リガンド)抗体およびその使用
|
JP2007503206A
(ja)
|
2003-08-22 |
2007-02-22 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
変更されたエフェクター機能を有する改良された抗体およびその抗体を産生する方法
|
US20050203063A1
(en)
|
2003-09-12 |
2005-09-15 |
Raymond Deshaies |
Proteasome pathway inhibitors and related methods
|
EP2168968B1
(en)
|
2004-04-02 |
2017-08-23 |
OSI Pharmaceuticals, LLC |
6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
|
UY28931A1
(es)
|
2004-06-03 |
2005-12-30 |
Bayer Pharmaceuticals Corp |
Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
|
AR053090A1
(es)
|
2004-07-20 |
2007-04-25 |
Osi Pharm Inc |
Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
|
UY29177A1
(es)
|
2004-10-25 |
2006-05-31 |
Astex Therapeutics Ltd |
Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
|
CN101106983A
(zh)
|
2004-11-24 |
2008-01-16 |
诺瓦提斯公司 |
JAK抑制剂与至少一种Bcr-Abl、Flt-3、FAK或RAF激酶抑制剂的组合
|
SI1951724T1
(sl)
|
2005-11-17 |
2011-09-30 |
Osi Pharmaceuticals Llc |
Kondenzirani biciklični mTOR inhibitorji
|
PE20070855A1
(es)
|
2005-12-02 |
2007-10-14 |
Bayer Pharmaceuticals Corp |
Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
|
KR20130141706A
(ko)
|
2005-12-02 |
2013-12-26 |
바이엘 헬스케어 엘엘씨 |
과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에 유용한 치환된 4-아미노-피롤로트리아진 유도체
|
ES2611588T3
(es)
|
2005-12-13 |
2017-05-09 |
Incyte Holdings Corporation |
Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
|
CA2633035C
(en)
|
2005-12-15 |
2016-05-10 |
Rigel Pharmaceuticals, Inc. |
Kinase inhibitors and their uses
|
KR101432316B1
(ko)
|
2006-04-12 |
2014-08-29 |
버텍스 파마슈티칼스 인코포레이티드 |
증식성 장애의 치료를 위한 단백질 키나제 plk1 억제제로서의 4,5-디히드로-[1,2,4]트리아졸로[4,3-f]프테리딘
|
EP2010528B1
(en)
|
2006-04-19 |
2017-10-04 |
Novartis AG |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
JP2009536161A
(ja)
|
2006-04-25 |
2009-10-08 |
アステックス、セラピューティックス、リミテッド |
医薬化合物
|
WO2008048375A1
(en)
|
2006-05-19 |
2008-04-24 |
Bayer Healthcare Ag |
Pyridonecarboxamide derivatives useful in treating hyper-proliferative and angiogenesis disorders
|
WO2008045978A1
(en)
|
2006-10-10 |
2008-04-17 |
Rigel Pharmaceuticals, Inc. |
Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
|
DE602007012473D1
(de)
|
2006-12-14 |
2011-03-24 |
Vertex Pharma |
Als proteinkinaseinhibitoren geeignete verbindungen
|
PT2078010E
(pt)
|
2006-12-29 |
2014-05-07 |
Rigel Pharmaceuticals Inc |
Triazoles substituídos com heteroarilos policíclicos úteis como inibidores de axl
|
ES2406930T3
(es)
|
2006-12-29 |
2013-06-10 |
Rigel Pharmaceuticals, Inc. |
Triazoles sustituidos con arilo bicíclico y heteroarilo bicíclico útiles como inhibidores de AXL
|
JP5567837B2
(ja)
|
2006-12-29 |
2014-08-06 |
ライジェル ファーマシューティカルズ, インコーポレイテッド |
Axlインヒビターとして有用なN3−ヘテロアリール置換トリアゾールおよびN5−ヘテロアリール置換トリアゾール
|
US8168415B2
(en)
|
2007-02-07 |
2012-05-01 |
The Regents Of The University Of Colorado |
Axl fusion proteins as Axl tyrosine kinase inhibitors
|
CN101652141A
(zh)
*
|
2007-03-29 |
2010-02-17 |
万能药生物有限公司 |
他克莫司的调节释放剂型
|
MX2009013565A
(es)
*
|
2007-06-12 |
2010-06-02 |
Concert Pharmaceuticals Inc |
Derivados de azapeptidos.
|
NZ583061A
(en)
|
2007-08-15 |
2012-06-29 |
Vertex Pharma |
4-(9-(3,3-difluorocyclopentyl)-5,7,7-trimethyl-6-oxo-6,7,8,9-tetrahydro-5h-pyrimido[4,5-b[1,4]diazepin-2-ylamino)-3-methoxybenzamide derivatives as inhibitors of the human protein kinases plk1 to plk4 for the treatment of proliferative diseases
|
GB0719803D0
(en)
|
2007-10-10 |
2007-11-21 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
AU2008315746A1
(en)
|
2007-10-25 |
2009-04-30 |
Astrazeneca Ab |
Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders
|
ES2424259T3
(es)
|
2007-10-26 |
2013-09-30 |
Rigel Pharmaceuticals, Inc. |
Triazoles sustituidos con arilo policíclico y heteroarilo policíclico, útiles como agentes inhibidores del Axl
|
BRPI0821209A2
(pt)
|
2007-12-19 |
2019-09-24 |
Amgen Inc |
composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
|
AR070127A1
(es)
|
2008-01-11 |
2010-03-17 |
Novartis Ag |
Pirrolo - pirimidinas y pirrolo -piridinas
|
RU2010146474A
(ru)
|
2008-04-16 |
2012-05-27 |
Макс-Планк-Гезелльшафт Цур Фердерунг Дер Виссеншафтен Е.Ф. (De) |
Производные хинолина в качестве ингибиторов axl киназ
|
TWI539953B
(zh)
|
2008-04-28 |
2016-07-01 |
瑞波若斯治療學公司 |
用於治療乳癌之組成物和方法
|
KR20110039278A
(ko)
|
2008-06-23 |
2011-04-15 |
버텍스 파마슈티칼스 인코포레이티드 |
단백질 키나제 억제제
|
ES2399319T3
(es)
|
2008-07-09 |
2013-03-27 |
Rigel Pharmaceuticals, Inc. |
Triazoles sustituidos con heteroarilos bicíclicos que contienen puentes útiles como inhibidores de AXL
|
CA2730231C
(en)
|
2008-07-09 |
2016-10-18 |
Rigel Pharmaceuticals, Inc. |
Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
|
US20120230991A1
(en)
|
2008-07-29 |
2012-09-13 |
Douglas Kim Graham |
Methods and compounds for enhancing anti-cancer therapy
|
EP2158913A1
(en)
|
2008-08-25 |
2010-03-03 |
Ratiopharm GmbH |
Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
|
US20100075973A1
(en)
|
2008-08-28 |
2010-03-25 |
Takeda Pharmaceutical Company Limited |
Polo-like kinase inhibitors
|
TW201035100A
(en)
|
2008-12-19 |
2010-10-01 |
Cephalon Inc |
Pyrrolotriazines as ALK and JAK2 inhibitors
|
JP2012517426A
(ja)
|
2009-02-09 |
2012-08-02 |
アステックス ファーマシューティカルズ インコーポレイテッド |
ピロロピリミジニルaxlキナーゼ阻害剤
|
US8765754B2
(en)
|
2009-04-29 |
2014-07-01 |
Locus Pharmaceuticals, Inc. |
Pyrrolotriazine compounds
|
EA025520B1
(ru)
|
2009-05-22 |
2017-01-30 |
Инсайт Холдингс Корпорейшн |
N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛ-ПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
|
CN104945420A
(zh)
|
2009-06-29 |
2015-09-30 |
因塞特公司 |
作为pi3k抑制剂的嘧啶酮类
|
TW201113285A
(en)
|
2009-09-01 |
2011-04-16 |
Incyte Corp |
Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
|
WO2011038185A2
(en)
|
2009-09-25 |
2011-03-31 |
Vertex Pharmaceuticals Incorporated |
Methods for preparing pyrimidine derivatives useful as protein kinase inhibitors
|
EP2311809A1
(en)
|
2009-10-16 |
2011-04-20 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Quinolinyloxyphenylsulfonamides
|
US8604217B2
(en)
|
2009-11-12 |
2013-12-10 |
Selvita S.A. |
Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
|
TW201130842A
(en)
|
2009-12-18 |
2011-09-16 |
Incyte Corp |
Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors
|
NZ602313A
(en)
|
2010-03-10 |
2014-08-29 |
Incyte Corp |
Piperidin-4-yl azetidine derivatives as jak1 inhibitors
|
US8791257B2
(en)
|
2010-03-31 |
2014-07-29 |
Bristol-Myers Squibb Company |
Substituted pyrrolotriazines as protein kinase inhibitors
|
CN102471342A
(zh)
|
2010-05-05 |
2012-05-23 |
沃泰克斯药物股份有限公司 |
用作PKC-θ抑制剂的4取代的吡唑并吡啶类
|
EP2423208A1
(en)
|
2010-08-28 |
2012-02-29 |
Lead Discovery Center GmbH |
Pharmaceutically active compounds as Axl inhibitors
|
RU2014118677A
(ru)
|
2010-10-08 |
2015-11-20 |
Элан Фармасьютикалз, Инк. |
Ингибиторы киназ типа polo
|
ITRM20100537A1
(it)
|
2010-10-12 |
2012-04-12 |
Consiglio Nazionale Ricerche |
Aptamero inibitore del recettore tirosina chinasi axl per uso in terapia
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
AR084366A1
(es)
|
2010-12-20 |
2013-05-08 |
Incyte Corp |
N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
|
ES2590778T3
(es)
|
2011-02-28 |
2016-11-23 |
Calitor Sciences, Llc |
Compuestos de quinolina sustituida
|
CA2830516C
(en)
|
2011-03-23 |
2017-01-24 |
Amgen Inc. |
Fused tricyclic dual inhibitors of cdk 4/6 and flt3
|
HUE046988T2
(hu)
|
2011-04-01 |
2020-04-28 |
Univ Utah Res Found |
Szubsztituált N-fenilpirimidin-2-amin analógok mint AXL kináz inhibitorok
|
AR086913A1
(es)
*
|
2011-06-14 |
2014-01-29 |
Novartis Ag |
4-metil-3-[[4-(3-piridinil)-2-pirimidinil]-amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil]-benzamida amorfa, forma de dosificacion que la contiene y metodo para prepararlas
|
WO2012177606A1
(en)
|
2011-06-20 |
2012-12-27 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
CA2840518A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為jak抑制劑之環己基氮雜環丁烷衍生物
|
HUE043703T2
(hu)
|
2011-09-02 |
2019-09-30 |
Incyte Holdings Corp |
Heterociklusos aminok PI3K inhibitorokként
|
PL2758052T3
(pl)
|
2011-09-18 |
2018-10-31 |
Euro-Celtique S.A. |
Kompozycja farmaceutyczna zawierająca inhibitor HDAC i cyklopolisacharyd
|
CN102408411B
(zh)
|
2011-09-19 |
2014-10-22 |
北京康辰药业股份有限公司 |
一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
|
CA2850617A1
(en)
|
2011-10-03 |
2013-04-11 |
The University Of North Carolina At Chapel Hill |
Pyrrolopyrimidine compounds for the treatment of cancer
|
EP3045453A1
(en)
|
2011-11-14 |
2016-07-20 |
Cephalon, Inc. |
Uracil derivatives as axl and c-met kinase inhibitors
|
EA027603B1
(ru)
|
2011-11-29 |
2017-08-31 |
Перосфере Инк. |
Производные пиперазина, реверсирующие действие антикоагулянтов
|
EP2788000B1
(en)
|
2011-12-06 |
2018-05-30 |
Merck Sharp & Dohme Corp. |
Pyrrolopyrimidines as janus kinase inhibitors
|
KR102078530B1
(ko)
|
2012-01-31 |
2020-02-18 |
다이이찌 산쿄 가부시키가이샤 |
피리돈 유도체들
|
US9475815B2
(en)
|
2012-02-23 |
2016-10-25 |
Bayer Intelletual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
WO2013162061A1
(ja)
|
2012-04-26 |
2013-10-31 |
第一三共株式会社 |
二環性ピリミジン化合物
|
US9193733B2
(en)
|
2012-05-18 |
2015-11-24 |
Incyte Holdings Corporation |
Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
|
CN104981247A
(zh)
|
2012-09-06 |
2015-10-14 |
普莱希科公司 |
用于激酶调节的化合物和方法及其适应症
|
EP2900673A4
(en)
|
2012-09-26 |
2016-10-19 |
Univ California |
MODULATION OF IRE1
|
EP2909211A4
(en)
|
2012-10-17 |
2016-06-22 |
Univ North Carolina |
PYRAZOLOPYRIMIDINE COMPOUNDS FOR CANCER TREATMENT
|
CN104918945B
(zh)
|
2012-11-01 |
2018-01-05 |
因赛特公司 |
作为jak抑制剂的三环稠合噻吩衍生物
|
CN104936963B
(zh)
|
2012-11-20 |
2017-11-28 |
普罗齐纳斯有限公司 |
作为蛋白激酶抑制剂的硫醚衍生物
|
US20140199728A1
(en)
|
2013-01-14 |
2014-07-17 |
Amgen Inc. |
Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
|
WO2014164729A1
(en)
|
2013-03-12 |
2014-10-09 |
Arqule, Inc. |
Substituted tricyclic pyrazolo-pyrimidine compounds
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
WO2015068767A1
(ja)
|
2013-11-08 |
2015-05-14 |
小野薬品工業株式会社 |
ピロロピリミジン誘導体
|
WO2015132799A2
(en)
|
2014-02-03 |
2015-09-11 |
Cadila Healthcare Limited |
Novel heterocyclic compounds
|
GB201420285D0
(en)
|
2014-11-14 |
2014-12-31 |
Bergenbio As |
Process
|
JP6621477B2
(ja)
|
2014-12-18 |
2019-12-18 |
ファイザー・インク |
ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用
|
US9840503B2
(en)
|
2015-05-11 |
2017-12-12 |
Incyte Corporation |
Heterocyclic compounds and uses thereof
|
DK3328419T3
(da)
|
2015-07-30 |
2021-10-11 |
Macrogenics Inc |
Pd-1-bindingsmolekyler og fremgangsmåder til anvendelse deraf
|
WO2017027717A1
(en)
|
2015-08-12 |
2017-02-16 |
Incyte Corporation |
Bicyclic fused pyrimidine compounds as tam inhibitors
|
US10053465B2
(en)
|
2015-08-26 |
2018-08-21 |
Incyte Corporation |
Pyrrolopyrimidine derivatives as TAM inhibitors
|
WO2017062797A1
(en)
|
2015-10-07 |
2017-04-13 |
The University Of North Carolina At Chapel Hill |
The methods for treatment of tumors
|
CA3000803C
(en)
|
2015-10-13 |
2020-03-24 |
Nihon Nohyaku Co., Ltd. |
Oxime group-containing condensed heterocyclic compound or salt thereof, agricultural and horticultural insecticide comprising the compound, and method for using the insecticide
|
EP3373934B1
(en)
|
2015-11-14 |
2020-05-20 |
Sunshine Lake Pharma Co., Ltd. |
Crystalline form of a substituted quinoline compound and pharmaceutical compositions thereof
|
ES2911678T3
(es)
|
2015-11-14 |
2022-05-20 |
Sunshine Lake Pharma Co Ltd |
Forma cristalina de un compuesto de quinolina sustituida y composiciones farmacéuticas de la misma
|
CA3019145A1
(en)
|
2016-03-28 |
2017-10-05 |
Incyte Corporation |
Pyrrolotriazine compounds as tam inhibitors
|
JP6999574B2
(ja)
|
2016-04-22 |
2022-01-18 |
インサイト・コーポレイション |
Lsd1阻害剤の製剤
|
US10138248B2
(en)
|
2016-06-24 |
2018-11-27 |
Incyte Corporation |
Substituted imidazo[2,1-f][1,2,4]triazines, substituted imidazo[1,2-a]pyridines, substituted imidazo[1,2-b]pyridazines and substituted imidazo[1,2-a]pyrazines as PI3K-γ inhibitors
|
JOP20170153A1
(ar)
|
2016-07-15 |
2019-01-30 |
Lilly Co Eli |
نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
|
EP3484524B1
(en)
|
2016-07-15 |
2022-11-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of smn2
|
JOP20190257A1
(ar)
|
2017-04-28 |
2019-10-28 |
Novartis Ag |
مركبات أريل غير متجانسة ثنائية الحلقة مندمجة 6-6 واستخدامها كمثبطات lats
|
LT3687996T
(lt)
|
2017-09-27 |
2022-01-10 |
Incyte Corporation |
Pirolotriazino darinių druskos, naudingos kaip tam inhibitoriai
|
PE20211805A1
(es)
|
2018-06-29 |
2021-09-14 |
Incyte Corp |
Formulaciones de un inhibidor de axl/mer
|
AU2021230385A1
(en)
|
2020-03-06 |
2022-09-22 |
Incyte Corporation |
Combination therapy comprising AXL/MER and PD-1/PD-L1 inhibitors
|